United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$323.88 USD
-5.37 (-1.63%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $323.46 -0.42 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 501 - 520 ( 596 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Financials Beat on Top Line And Double-Digit Growth Intact; 2013 Focus Remains On New Products And Growth; Reiterate OUTPERFORM & $91 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Preview: We Believe Consensus Is Achievable; In 2013, We See New Product Progress And Continued Sales Growth; Reiterate OUTPERFORM And $91 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Emerging Pharmaceuticals - April and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
2012 Financials Beat And Double Digit Growth Intact. Near- Term Focus Remains On March 31st PDUFA For Oral Treprostinil. Reiterate OUTPERFORM & $91 FV.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Preview: We Believe Consensus Is Achievable, But Focus Is On March 31st PDUFA For Oral Treprostinil
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Pulling A Rabbit Out Of Its Hat: FDA Accepts Rapid Resubmission Of Oral Treprostinil NDA With Class 1 Review And March 31 PDUFA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Revenues And Earnings Beat (Again) And We Project Consistent Double Digit Growth Through 2016. Reiterate OUTPERFORM and $91 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Preview: We Believe Street Estimates Are Achievable;
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Oral Treprostinil Receives CRL Instead of Approval; We Recommend Buying On Weakness; Reiterate OUTPERFORM And $91 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
LIFE SCIENCES - The Week Ahead in Life Sciences - Upcoming Events for the Week of October 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
We Believe Self-Injected Treprostinil Could Be Important For Life-Cycle Management;
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L